(Q37997020)

26 August 2017

title

The therapeutic potential of the endocannabinoid system for Alzheimer's disease (English)

1 reference

26 August 2017

0 references

endocannabinoid system

0 references

Tim Karl

1

0 references

author name string

David Cheng

series ordinal

2

1 reference

26 August 2017

Brett Garner

series ordinal

3

1 reference

26 August 2017

Jonathon C Arnold

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

27 March 2012

1 reference

Expert Opinion on Therapeutic Targets

26 August 2017

published in

1 reference

26 August 2017

volume

16

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

407-420

1 reference

Is pharmacological prevention of Alzheimer's a realistic goal?

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Animal models of Alzheimer's disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Investigation of 15 of the top candidate genes for late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Intracellular amyloid-beta in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Glutamate and other CSF amino acids in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The cholinergic system in aging and neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Pathways of tau fibrillization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Inflammation and aging: can endocannabinoids help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Microglia and Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Immunotherapeutic Approaches to Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

In-vivo measurement of activated microglia in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Alzheimer neuropathologic alterations in aged cognitively normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Pathways towards and away from Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Alzheimer's disease as homeostatic responses to age-related myelin breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The endocannabinoid system and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Endocannabinoids and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Vitamin C and Vitamin E for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Vascular pharmacotherapy and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabinoids and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Endocannabinoid tone versus constitutive activity of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The major plant-derived cannabinoid Δ(9)-tetrahydrocannabinol promotes hypertrophy and macrophage infiltration in adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates receptor-mediated neurotoxicity in primary cultures of rat forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

A molecular link between the active component of marijuana and Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Emerging roles for endocannabinoids in long‐term synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Disruptive effects of the prototypical cannabinoid Δ⁹-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Enhancement of memory in cannabinoid CB1 receptor knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Alzheimer's disease; taking the edge off with cannabinoids?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Molecular reorganization of endocannabinoid signalling in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol: a promising drug for neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

The clinical use of structural MRI in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.671812

10.1517/14728222.2012.671812

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference